Abstract Background: Ovarian teratocarcinoma (OVTC) arises from germ cells and contains a high percentage of cancer stem/progenitor cells (CSPCs), which promote cancer development through their ability to self-renew. Androgen and androgen receptor (androgen/AR) signaling has been reported to participate in cancer stemness in some types of cancer; however, this phenomenon has never been studied in OVTC. Methods: Ovarian teratocarcinoma cell line PA1 was manipulated to overexpress or knockdown AR by lentiviral deliver system. After analyzing of AR expression in PA1 cells, cell growth assay was assessed at every given time point. In order to determine ligand effect on AR actions, luciferase assay was performed to evaluate endogenous and exogenous AR function in PA1 cells. CD133 stem cell marker antibody was used to identify CSPCs in PA1 cells, and AR expression level in enriched CSPCs was determined. To assess AR effects on CD133 + population progression, stem cell functional assays (side population, sphere formation assay, CD133 expression) were used to analyze role of AR in PA1 CSPCs. In tissue specimen, immunohistochemistry staining was used to carry out AR and CD133 staining in normal and tumor tissue. Results: We examined androgen/AR signaling in OVTC PA1 cells, a CSPCs-rich cell line, and found that AR, but not androgen, promoted cell growth. We also examined the effects of AR on CSPCs characteristics and found that AR expression was more abundant in CD133 + cells, a well-defined ovarian cancer stem/progenitor marker, than in CD133 − populations. Moreover, results of the sphere formation assay revealed that AR expression was required to maintain CSPCs populations. Interestingly, Abbreviations: CSPCs, cancer stem/progenitor cells; OVTC, ovarian teratocarcinoma; AR, androgen receptor; DHT, 5α-dihydrotestosterone; DMEM, Dulbecco's modified Eagle medium; Ct, threshold value; hrEGF, human recombinant epidermal growth factor; hrbFGF, human recombinant basic fibroblast growth factor. this AR-governed self-renewal capacity of CSPCs was only observed in CD133 + cells. In addition, we found that AR-mediated CSPCs enrichment was accompanied by down-regulation of p53 and p16. Finally, co-expression of AR and CD133 was more abundant in OVTC lesions than in normal ovarian tissue. Conclusion The results of this study suggest that AR itself might play a ligand-independent role in the development of OVTC.
Introduction
Ovarian tumors are classified according to the assumed cell type of origin, namely surface epithelium (ovarian carcinoma), stroma (ovarian adenoma), salpin (fallopian tube cancer), and germ cells (ovarian teratoma) (Zhang et al., 2008; Koshy et al., 2005; Wasim et al., 2009) . Ovarian teratoma, a mixed germ cell tumor, comprises approximately 20% of ovarian neoplasms (Sviracevic et al., 2011; Oliveira et al., 2004; Moniaga and Randall, 2011) . Teratocarcinoma (OVTC), a very aggressive ovarian tumor, accounts for approximately 10-15% of germ cell tumor (Koshy et al., 2005; Sviracevic et al., 2011; Oliveira et al., 2004; Moniaga and Randall, 2011) ; however, the pathogenesis of this type of tumor is poorly understood. It is well known that sex steroid hormones such as androgens, estrogens, and progesterone play pivotal roles in reproductive function throughout reproductive ages (Walters et al., 2008; Ahmad and Kumar, 2011) ; however, little is known about their impact on OVTC development and progression.
Cancer stem/progenitor cells (CSPCs) are thought of as a confounding factor for carcinogenesis and cancer progression because of their capacity for unlimited self-renewal. Studies have shown that several glycoproteins, namely CD133 (Baba et al., 2009; Chen et al., 2014) , CD117 (Luo et al., 2011) , CD24 (Gao et al., 2010) , and CD44 (Meng et al., 2012) , as well as the transcription factors OCT-4 (Jiao et al., 2013) and Nanog (Lee et al., 2012) , are markers of CSPCs in ovarian tissue. PA1, an OVTC cell line, is an excellent cell line for studying cancer stem cell characteristics because it abundantly expresses the CSPCs marker CD133 (Skubitz et al., 2013; Guo et al., 2011; Chung et al., 2013) . In addition to using biomarkers to distinguish CSPCs, analysis of sphere-forming capacity is also a reliable method for detecting and characterizing CSPCs populations (Chung et al., 2013; Williams et al., 2010; Szotek et al., 2006; Fong and Kakar, 2010) .
Androgens play important roles in both male and female reproductive organs Fauser et al., 2011; Matsumoto et al., 2008) . The androgens act through the androgen receptor (AR), a transcription factor that belongs to the nuclear receptor superfamily . AR exerts physiological and pathological functions in organisms by translocating to the nucleus upon binding to androgens, where it binds to specific DNA sequences (Wang et al., 2005 (Wang et al., , 2009 Ma et al., 2012a) . However, non-classical androgen/AR action has been documented in a variety of pathophysiological conditions (Simoncini and Genazzani, 2003; Baron et al., 2004; Singh et al., 2006; Bonaccorsi et al., 2006) . There are two types of non-classical androgen/AR actions: ligand-mediated transient androgen/AR actions and ligand-independent AR actions (Fujimoto et al., 2001; Heinlein and Chang, 2002; Kousteni et al., 2001; Losel et al., 2003) . Ligand-mediated transient androgen/AR actions are stimulated by its binding to androgen, while ligand-independent AR actions are mediated by growth factors (Culig et al., 1994) , or protein kinases (Lyons et al., 2008; Culig, 2004) . However, both types of nonclassical actions are the result of the translocation of AR to the nucleus where it acts as a DNA-binding transcription factor that regulates target gene expression. In this study, we examined whether androgen/AR signaling is involved in the development of OVTC in vitro and in humans.
Materials and methods
Ovarian teratocarcinoma patient data from a single cohort study Specimens of ovarian teratocarcinoma (n = 7) analyzed in this study were obtained from patients who had received the diagnosis during the period 1987-2013 at the China Medical University (Taichung, Taiwan). Patients were identified from a single cohort registered in the Cancer Registry Database of the hospital. Access to the tissue samples was approved by the Internal Review Board of the China Medical University Hospital (#DMR101-IRB2-276).
Cell culture
The human OVTC cell line (PA1), the human embryonic kidney cell line (HEK293T), and the human prostate adenocarcinoma cell line (LnCap) were cultured in Dulbecco's modified Eagle medium (DMEM) (GIBCO, CA, USA) with 10% fetal calf serum (FCS) (GIBCO, CA, USA) and 1% penicillin/streptomycin (GIBCO, CA, USA). PA1 and LnCap cells were provided courtesy of Dr. Min-Chie Hung (MD Anderson, TX, USA) and HEK293T cells were obtained from Dr. Yuh-Pyng Shyr (Center of Molecular Medicine, China Medical University Hospital, Taichung, Taiwan). The cell lines were maintained at 37°C in a humidified atmosphere of 5% CO 2 .
Western blotting assay
Protein extraction and the immunoblot assay were performed as previously described (Ma et al., 2012b) . Briefly, cells were washed with 1× PBS and resolved in RIPA buffer (100 mM Tris, 5 mM EDTA, 5% NP40; pH 8.0) with protease inhibitors (1 mM phenyl-methyl sulphonyl fluoride, 1 μg/ml aprotinin, 1 μg/ml leupeptin). Proteins were resolved by SDS-PAGE and then transferred to PVDF membranes. Blocking of non-specific binding was accomplished by adding 5% non-fat milk. After application of primary antibodies (AR, N-20 Santa Cruz, CA, USA; β-actin, Santa Cruz, CA, USA; p53 (FL-393), Santa Cruz, CA, USA; p16 (F-12) Santa Cruz, CA, USA), secondary antibodies (1:3000, HRP-goat-anti-mouse and HRP-goat-anti-rabbit) were applied for 1 h at room temperature. Signals were enhanced using an ECL chemiluminescence kit (Millipore, MA, USA) and detected by ChemiDoc™ XRS+ (Bio-Rad, CA, USA).
Transfection and infection procedure
The lentiviral production and infection procedures were carried out as reported previously, with minor modifications (Ma et al., 2012b; Lee et al., 2013) . Briefly, cells were transfected with the following lentivirus plasmids: psPAX2 packaging plasmid, pMD2G envelope plasmid (Addgen, MA, USA), pWPI-vector ctrl, and pWPI-hAR. Lentiviral plasmids carrying the GFP gene were co-transfected with psPAX2 and pMD2G into HEK293T cells at a ratio of 3:2:4 by lipofectamine 2000 (Invitrogen, CA, USA) as per the manufacturer's instructions. After 6 h, the medium was replaced with fresh DMEM/10% FBS medium and cells were maintained at 37°C in a humidified incubator in an atmosphere of 5% CO 2 for 48 h. Medium containing virus was collected by centrifugation and filtered through a 0.45 μm filter. Medium containing 0.8 mg/ml polybrene (Sigma-Aldrich, MO, USA) was then added to culture dishes containing 10 6 PA1 cells. After 16 h of infection, the medium containing virus was replaced with fresh DMEM/10% FBS medium and cells were maintained at 37°C in a humidified incubator in an atmosphere of 5% CO 2 for 48 h. Infected cells were then collected and analyzed. The green fluorescence protein (GFP)+ cells were measured by flowcytometry (BD, CA, USA, LSR II Flow Cytometry) to determine infection efficiencies. GFP+ cells with infection efficiencies greater than 85% were subjected to the following experiments.
Total RNA isolation and cDNA synthesis RNA was extracted from PA1 cells as reported previously (Ma et al., 2012b) . Briefly, cells that had reached 80-90% confluence in 100-mm dishes were lysed with 1 ml Trizol (Invitrogen, CA, USA). Phenol/chloroform was then added and RNA-rich layers were separated by centrifugation. Soluble RNA was precipitated with 2-propanol. RNA was then rinsed with 75% ethanol and then dissolved in RNase-free water. For first-strand cDNA synthesis, 5 μg of total RNA was used to perform reverse transcription PCR by the PrimeScript™ RT reagent kit (TAKARA Bio Inc., Kyoto, Japan). cDNA was synthesized according to the manufacturer's instructions.
Quantitative real-time PCR analysis
A real-time detection system (Bio-Rad Laboratories, Inc., CA, USA) and the KAPA™ SYBR FAST One-Step qRT-PCR Kit (KAPABIOSYSTEMS, MA, USA) were used according to the manufacturers' instructions. Relative gene expression was determined by normalizing the expression level of the target gene to the expression level of a housekeeping gene (β-actin). Threshold value (Ct) dynamics were used (2 − ΔΔCt ) for quantitation of gene expression. The qRT-PCR primer sequences were as follows: CD133 forward 5′-TCT CTA TGT GGT ACA GCC G-3′, reverse 5′-TGA TCC GGG TTC TTA CCT G-3′; CD24 forward 5′-TTT ACA ACT GCC TCG ACA CAC ATA A-3′, reverse 5′-CCC ATG TAG TTT TCT AAA GAT GGA A-3′; CD44 forward 5′-GAC CTC TGC AAG GCT TTC AA-3′, reverse 5′-TCC GAT GCT CAG AGC TTT CTC-3′; CD117 forward 5′-CAA GGA AGG TTT CCG AAT GC-3′, reverse 5′-CCA GCA GGT CTT CAT GAT GT-3′; Nanog forward 5′-GGG CCT GAA GAA AAC TAT CCA TCC-3′, reverse 5′-TGC TAT TCT TCG GCC AGT TGT TTT-3′; OCT-4 forward 5′-GGC CCG AAA GAG AAA GCG AAC C-3′, reverse 5′-ACC CAG CAG CCT CAA AAT CCT CTC-3′; SCF forward 5′-ACT GAC TCT GGA ATC TTT CTC AGG-3′, reverse 5′-GAT GTT TTG CCA AGT CAT TGT TGG-3′.
Cell growth analysis
The WST-1 assay (Roche, Basel, Switzerland) was used to assess cell growth. Briefly, 10 3 cells/100 μl/well were seeded in 96-well plates with DMEM in 10% charcoal-dextran treated FBS (CDFBS) and were incubated for designated time periods (1, 2, 4, 6, 8 days). Then, 10 μl of WST-1 solution was added to each well and cells were allowed to incubate at 37°C in an incubator for an hour. Cell viability was quantified by colorimetric detection in an ELISA plate reader (BECKMAN, Il, USA, COULTER PARADIGM™ Detection Platform) at an absorbance of 450 nm and 690 nm to generate an OD proportional to the relative abundance of live cells in the given wells.
Colony formation assay and Standard cell number count
Two sets of 1.5 × 10 5 cells/dish were seeded in 6-cm plates with DMEM in 10% CDFBS and incubated for 8 days. In one set of cells, 1000 μl of 4% formaldehyde solution was added to fixed cells and the cells were allowed to incubate at room temperature for one hour. Crystal violet cell staining was then performed. After 1 h, crystal violate was washed from the cell culture dish and cell colonies were photographed. The other set of cells were subjected for cell counting.
Luciferase assay
The assay was performed as previously described (Lyons et al., 2008) . Briefly, pGL3-ARE (androgen response element-driven luciferase reporter plasmid) and pRL-TK (thymidine kinase promoter-driven renilla luciferase plasmid) were transiently co-transfected into cells. After 6 h, medium was replaced with fresh medium and 10% CDFBS. Cells were then cultured for 48 h with or without DHT (10 nM). After 24 h, cells were washed with 1 × PBS and then incubated in the presence of 100 μl CCLR (cell culture lysis reagent) (Promega, WI, USA) at room temperature for 30 min. Cell lysates were then placed in a microtube and centrifuged at 14,000 rpm for 5 min. Supernatant (5 μl) was then mixed with 50 μl luciferase assay reagent. Luciferase activity was measured immediately using a luminescence microplate reader and presented as relative luminescence units.
Side population analysis
Side population analysis was preformed as described previously by Goodell (Hirschmann-Jax et al., 2004) . Briefly, 10 6 cells were detached and washed, and then incubated in DMEM containing 2% FCS and 5 μg/ml Hoechst33342 dye (SigmaAldrich, MO, USA) for 90 min at 37°C, either alone or in the presence of 50 μM verapamil (Sigma-Aldrich, MO, USA). After certain incubation time periods, cells were washed with ice-cold 1 × PBS and then resuspended with 1× PBS supplemented with 2% FCS and 2 μg/ml propidium iodide (SigmaAldrich, MO, USA) at 4°C for 5 min, to exclude dead cells. The cells were analyzed using flowcytometry (BD, CA, USA, LSR II Flow Cytometry) with dual wavelength analysis (Hoechst-blue, 424-444 nm; Hoechst-red, 675 nm) after excitation with 350 nm UV light.
Verification and sorting of CD133 + cells
Cells were detached with 1% trypsin/EDTA and cell membrane non-specific binding to antibodies was blocked by 5% BSA for 30 min at room temperature. Cells were then incubated with antibody CD133-APC (MACS, Miltenyi Biotech, Gladbach, Germany) for 30 min and then subjected to flowcytometry (FACS, BD, CA, USA, FACSAria) analysis. The CD133 +/− cells were collected by a cell sorter (BD, CA, USA, FACSAria).
Sorting of CD133 + and CD133 − populations
A CD133 MicroBead kit (Miltenyi Biotec, Gladbach, Germany) was used to sort PA1 CD133+ cells according to the manufacturer's instructions. Briefly, 10 8 cells were washed, resuspended in 300 μl of buffer (1X PBS/pH 7.2, 0.5% BSA/ 2 mM EDTA) with 100 μl FcR Blocking Reagent and 100 μl of CD133 MicroBeads, mixed well, and then incubated for 30 min at 2-8°C. The labeled cells were then washed, resuspended in 500 μl buffer, and then applied to a MACS Column to collect unlabeled cells (CD133− cells). Finally, the column was removed from the magnet and placed in collection tubes to collect magnetically-labeled cells (CD133 + cells).
Sphere formation assay
Cells were collected and washed to remove serum and then suspended in serum-free DMEM supplemented with 20 ng/ml human recombinant epidermal growth factor (hrEGF), 10 ng/ml human recombinant basic fibroblast growth factor (hrbFGF), Figure 1 AR promotes OVTC PA1 cell growth. A. Western blotting (left-hand side) showed that AR expression was significantly higher in PA1 cells infected with AR cDNA (pWPI-hAR; AR) than in control cells (pWPI-vector ctrl; Vec). LnCap cells served as a positive control. The graph on the right-hand side is quantitation data of AR protein expression. B. AR cDNA promotes cell growth. WST-1 assays were performed at the indicated time points (1, 2, 4, 6, 8 days) . The Y-axis indicates the absolute light absorbance (Abs.; Abs. wave length at 450 nm deducted from that of 630 nm background readings). Vec and AR infected cells were compared. C. AR cDNA promotes cell growth. Cell number count was analyzed and photographed on day 8. D. Western blotting (left-hand side) showed that AR expression was significantly lower in PA1 cells infected with AR siRNA (pLKO.1-siAR; siAR) than in control cells (pLKO.1-si Luciferase; siLuc). LnCap cells served as a positive control. The graph on the right-hand side is the quantitation data of AR protein expression. E. AR siRNA suppressed cell growth. WST-1 assays were performed at the indicated time points (1, 2, 4, 6, 8 days) . The Y-axis indicates the absolute Abs. of siLuc and siAR infected cells. F. AR siRNA suppressed cell growth. Cell number count was analyzed and photographed on day 8. The results shown are from 3 independent experiments. *Indicates significance at a p-value less than 0.05. 5 μg/ml insulin, and 0.4% BSA (Sigma, USA). The cells were subsequently cultured in ultra low attachment 6-well plates (Corning Inc., Corning, NY, USA) at a density of less than 5000 cells/well for 14 days. Spheres were observed under a microscope and images were photographed under a phase contrast fluorescence microscope (Nikon, ECLIPSE 80i).
Statistical analysis
Statistical analyses were performed using the Student's t-test. All experiments were repeated at least three times, and p-values less than 0.05 were considered to indicate statistical significance.
Results

Ligand-independent AR actions promote OVTC cell growth
In order to test whether androgen/AR signaling plays a role in the development of OVTC, we first used a lentiviral-based delivery system to engineer AR-knockdown PA1 cells and PA1 cells that overexpress AR. Results of Western blot analysis showed that AR protein levels were approximately 40-fold higher in PA1 cells that were engineered to overexpress AR than in vector control cells (Fig. 1A) . In addition, we found that cells that overexpressed AR grew more rapidly than vector control cells (Figs. 1B and C) . In contrast, expression of AR (Fig. 1D) and rate of growth (Figs. 1E and F) were significantly lower in AR-knockdown PA1 cells than in nonspecific siRNA control cells.
We also tested the effects of androgen (5α-dihydrotestosterone; DHT 10 nM) on PA1 cell growth. As seen in Fig. 2A , DHT had little effect on PA1 cell growth. In order to better understand ligand-independent AR functions, ARE (androgen receptor response element) promoter assays were performed. As shown in Fig. 2B , DHT treatment did not induce luciferase activity in PA1 cells (Fig. 2B, 3rd vs. 4th lane) but resulted in significant activity in LnCaP cells (Fig. 2B, 1st vs. 2nd lane). We further ectopically introduced wild type AR cDNA into PA1 cells to observe AR transactivation function (Fig. 2C) . The result showed that luciferase activity was not induced in pWPI-vector control cells or in pWPI-AR transfected cells, although it resulted in marked luciferase activity in pWPI-AR transfected 293T cells.
The data in Figs. 1 and 2 demonstrate that AR promotes OVTC cell growth through a ligand-independent pathway.
AR promotes CSPCs characteristics
Studies have shown that CSPCs can trigger tumorigenesis and promote cancer progression and that AR can promote the growth of CSPCs in various cancers. We, therefore, tested whether AR regulates CSPCs in OVTC. We performed a cellsorting assay to isolate PA1 cells that expressed the glycoprotein CD133, a well-established biomarker of CSPCs in ovarian cancer. Using a cell sorter and CD133 antibody, we were able to distinguish between CD133 − and CD133 + cell populations (Fig. 3A) . The 5% extremes of the staining signal within the spectrum were defined as CD133 + and CD133 − cells. Then we confirmed CSPCs characteristics by examining other CSPCs marker genes (Fig. 3B) . We found that the levels of expression of CD133, CD24, OCT-4, Nanog, CD117, and Figure 2 Ligand-independent AR effects on OVTC PA1 cell growth. A. DHT effect on growth of PA1 cells. WST-1 assay was performed on DHT 10 nM treated PA1 cells at indicated time points (1, 2, 4, 6, 8 days). The Y-axis indicates the absorbance (Abs.). B. Endogenous AR transactivation activity was absent in PA1 cells. ARE-luciferase assay was performed in DHT 10 nM treated PA1 cells. Thymidine kinase promoter-driven Renila construct (pRL-TK) was co-transfected and measured as a transfection control. Relative ARE-luciferase activity (fold to EtOH) is presented as transactivation activity of AR. AR transactivation function in LnCap cells served as a positive control. C. Exogenous AR transactivation was absent in PA1 cells. AR cDNA (pWPI-hAR; AR) or vector control (pWPI-vector ctrl; Vec) was co-transfected with ARE-luciferase and pRL-TK in PA-1 cells to observe ARE-luciferase activity. The transfection was also performed in 293T cells as a positive control. The results shown are from 3 independent experiments. *Indicates a p-value less than 0.05. CD44 were markedly higher in CD133 + cells than in CD133 − cells. We then measured AR expression and found that AR expression was significantly higher in CD133 + cells than in CD133 − cells ( Fig. 3C; 2nd vs. 3rd lane) .
The data suggest that AR acts as a cancer progression promoter in CSPCs. In order to further investigate this finding, we performed a side population assay (Williams et al., 2010; Szotek et al., 2006) in PA1 cells that overexpressed AR cDNA and in AR-knockdown PA1 cells. Using verapamil, a calcium channel blocker, to differentiate stem populations, we found that overexpression of AR cDNA increased the side population from 2.3% to 7% (Fig. 4A) and that AR siRNA knockdown decreased the side population from 2.3% to 1% (Fig. 4B) . Moreover, we used flowcytometry to examine the effects of AR on CD133 populations. As shown in Figs. 4C and D, overexpression of AR resulted in an increase in CD133+ cells (7.5% to 43%) and knockdown of AR by siRNA resulted in a decrease in CD133 + cells (7.7% to 1.5%). Furthermore, we used the sphere formation assay to confirm the role that AR plays in CSPCs characteristics. As shown in Fig. 4E , AR cDNA resulted in an increase in sphere number and size, while AR siRNA had the opposite effect (Fig. 4F ).
Since we observed that AR promotes CSPCs enrichment, we conducted further studies to better understand its role in (progenitor) CSPCs and (non-progenitor) non-CSPCs. Using a lentiviral-based gene delivery, we measured gene transduction efficiencies with N 95% GFP + cells using the pWPI GFP-carrying vector (Fig. 5A) . Since the pLKO.1 vector does not carry the GFP gene, we treated PA1 cells with puromycin (5 μM) for 2 weeks and then selected puromycin-resistant cells. Then we sorted out CD133 +/− cells to perform the sphere formation assay. As shown in Fig. 5B , CD133 + cells formed larger spheres than CD133 − cells (Figs. 5B and C) . Knockdown or overexpression of AR in CD133 − cells showed little effect on sphere formation; however, knockdown of AR suppressed (Fig. 5B) and overexpression of AR dramatically enhanced (Fig. 5C ) sphere formation in CD133 + cells.
It has been documented that regulation of p53-p21 and Rbp16 tumor suppression pathways are associated with cellular senescence Chen et al., 2011; Serrano et al., 1997) and cancer stemness (Armesilla-Diaz et al., 2009; Zheng et al., 2008; Akala et al., 2008; Strauss et al., 2012) by controlling cell cycle. Furthermore, our previous study IgG-isotype-APC staining signal is presented on the left-hand side, and the CD133-APC staining signal is presented on the right-hand side of the histogram. As indicated in P2 and P3, the 5% extremes of the staining signal within the spectrum were defined as CD133 + and CD133 − cells. Negatively stained cells (P2, left-hand side 5%) and positively stained cells (P3, right-hand side 5%) were subjected to the cell sorter for analysis. B. CSPCs marker genes were more highly expressed in CD133 + cells than in CD133 − cells. CD133, CD24, OCT-4, Nanog, CD117, and CD44 mRNA expressions were measured by quantitative real-time PCR, and the relative expressions were calculated as 2 − ΔΔCt . C. AR protein was more highly expressed in CD133 + cells than in CD133 − cells. Western blotting assays (upper panel) were performed to detect the expression of AR, and quantified data are shown in the lower panel. All data are from at least three independent experiments. The variations are due to standard deviation, and * indicates statistical significance at p b 0.05.
indicated that AR down-regulated p53 expression in hepatocellular carcinoma (Ma et al., 2008) . Therefore, we performed immunoblot assays to see whether this was the case in OVTC CSPCs. As shown in Fig. 5D , we found that p53 and p16 were downregulated by AR in CD133+ cells, which might indicate that cancer stem cell stemness is associated with the down regulation of p53 and p16 (4th vs. 3rd lane, and 4th vs. 2nd lane). Meanwhile, this data was consisted with previous studies that inactivation of both p53-p21 and p16-Rb signaling pathway are involved in CSPCs progression (Chen et al., 2011) . Taken together, the results presented in Figs. 3 to 5 demonstrate that AR promotes self-renewal of CSPCs in CD133 + PA1 cells.
Co-expression of CD133 and AR in OVTC tissue
The in vitro data show that AR promotes OVTC cell growth by promoting self-renewal of CSPCs. We further examined the role AR has on CD133 expression in human OVTC tissue samples using an immunohistochemical approach. Expression levels of AR and CD133 in cancer tissue were compared with those in normal ovarian tissue taken from the same patient. As seen in Fig. 6 , it is markedly lower expression of AR and fewer co-expression of CD133 in normal ovarian epithelial cells (Figs. 6A and C) compared to that in ovarian tumor epithelial cells. Furthermore, the co-expression of AR and CD133 were more obviously in cytoplasm than nucleus (Figs. 6B and D) . Those observations strengthen our showed on the right-hand side C. AR enhanced CD133 expression and population. Flowcytometry was performed using CD133-APC conjugated antibody to measure Vec-and AR-infected PA1 CD133 expression (histogram on the left), and CD133 population (right-hand side of the bar graphs). D. AR knockdown suppressed CD133 expression and population. Flowcytometry was performed to measure siLuc-and siAR-infected PA1 CD133 expression (histogram on the left), and CD133 populations (right-hand side bar graphs). E. AR promotes CSPCs sphere formation. Sphere images of were taken by a phase-contrast microscope (100 ×) and are shown on the left-hand side. The quantitation of sphere numbers is shown on the right-hand side bar graph. F. AR knockdown suppressed CSPCs sphere formation. Sphere images of siLuc-and siAR-infected PA1 cells (day-1 and day-14) were taken by a phase-contrast microscope (100 ×) and are shown on the left-hand side. The quantitation of sphere numbers is shown on the right-hand side bar graph. All experiments were from at least 3 independent experiments where * indicates p-values less than 0.05.
hypothesis that ligand-independent AR function involved in the disease progression.
Discussion
Ligand-independent AR function in cancer growth and CSPCs self-renewal
In this study, we have demonstrated the first in vitro evidence that AR promotes OVTC development through a ligand-independent pathway.
The functions of AR in cancer development have mostly been studied in prostate cancer (Heinlein and Chang, 2004) . The current therapeutic paradigm for prostate cancer is androgen ablation therapy (Pienta and Bradley, 2006) . However, some studies have shown that ligand-independent activation of AR is responsible for relapsed prostate cancer after anti-androgen therapy (Culig, 2004; Taplin and Balk, 2004; Jenster, 1999 Jenster, , 2000 . Studies in prostate cancer cells reported that AR transactivation was mediated by growth factors, such as IGF-I, KGF, EGF (Culig et al., 1994) , and the CXCL12/CXCR14 axis (Kasina and Macoska, 2012) in the absence of androgen. Kasina and Mascoska's (2012) study illustrated that intracellular signals of those growth factors i.e. Rho GTPase (Lyons et al., 2008) , MAPK, or AKT pathway (Feldman and Feldman, 2001 ) play a role in the ligandindependent function of AR in prostate cancer cells. Therefore, ligand-independent functions of AR appear to be triggered by intracellular signaling molecules that translocate AR into the nucleus (Culig et al., 1994; Lyons et al., 2008; Kasina and Macoska, 2012; Feldman and Feldman, 2001 ). The results of those studies imply that targeting of those signals as well as AR would improve the effectiveness of therapy for advanced prostate cancer. In addition, our previous work demonstrated that AR enhanced CSPCs in specimens of endometrial cancer associated with Cisplatin resistance (Chen et al., 2014) .
In this study, we found two interesting, yet previously unreported phenomena: AR can exert biological functions in OVTC cells in a ligand-independent manner and AR function can promote cancer cell growth through a pathway that does not involve transactivation. One possibility of this ligandindependent AR function might be that AR acts as transcriptional factor co-factor to regulate gene expressions.
Pathophysiological roles of AR in OVTC
Few studies have provided evidence that androgen/AR play a role in OVTC. Previous studies (Chadha et al., 1993; Cardillo et al., 1998; Shintaku et al., 2011) showed that 84% of benign and malignant ovarian tumors expressed AR; yet, there is no clear distinction between AR expression and ovarian cancers of different cellular origins. Because of the rarity of OVTC, few studies have been conducted on the pathogenesis of the disease. Herein, we have demonstrated that AR promotes the development and progression of OVTC by influencing tumorigenic CD133 + CSPCs populations. Furthermore, this is the first study showing that a male hormone receptor promotes ovarian cancer in a ligand-independent manner. p53 and p16 are involved in ligand-independent-AR-regulated OVTC CSPC progression
The tumor suppressor protein p53 plays a pivotal role in cell cycle arrest, senescence, DNA repair and programmed cell death. An abundance of evidence shows that p53 plays a critical role in self-renewal and differentiation of various cancer stem cells by controlling the cell cycle (Armesilla-Diaz et al., 2009; Zheng et al., 2008; Akala et al., 2008) . Furthermore, our previous study demonstrated that AR suppressed p53 expression in murine hepatic cells and that loss of hepatic AR promoted p53-mediated DNA damage sensing and repair systems as well as apoptosis (Ma et al., 2008). Our findings demonstrated that AR expression promotes self-renewal of CSPCs. Studies have shown that expression of the tumor suppressor gene p16 results in cell cycle arrest by inhibiting CDK4 and CDK6 (Akala et al., 2008; Strauss et al., 2012) . Its downregulation was also reported to be essential for cellular quiescence in cancer stem cells Chen et al., 2011; Armesilla-Diaz et al., 2009; Strauss et al., 2012) . Notably, the p53-p21 and p16-Rb pathways are two important arms converging cellular senescence that attenuates tumorigenicity while they were inactivated Chen et al., 2011; Serrano et al., 1997; Armesilla-Diaz et al., 2009; Zheng et al., 2008; Akala et al., 2008) .
In this study, we found that overexpression of AR in CD133 + cells was associated with down-regulation of p53 and p16 (Fig. 5D ). This result not only supports our previous finding that AR plays an important role in the progression of hepatoma (Ma et al., 2008) , but also provides evidence that CSPCs progression is mediated by ligand-independent AR-p53/p16 signaling. Taken together, our data indicate that AR controls OVTC CSPC progression by regulating, in a ligand-independent manner, p53-and p16-related events, such as cell cycle regulation.
Conclusion
The present study provides evidence that expression of AR in the absence of increased AR-mediated transcription exerts biological functions which indicates that ligand-independent AR function in CSPCs (e.g. CD133 + cells) facilitates OVTC cell growth, and that the expression of AR in CSPCs is accompanied by down-regulation of p53 and p16 (Fig. 7) .
Our data not only demonstrate a novel mechanism by which AR regulates cancer cell behavior, but also provides pathological insights into germ cell tumors. 
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